explore -WSS

explore

author：focus 2025-09-27 12:55:26 - browse：862

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Opioid cravings were reduced by anti

WSS

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Secretariat’s lessons for human medicine

As AI regulations shape up, health tech startups beg for clarity

Congress may force more Covid

Hospitals are piloting generative AI tools as regulators play catch

Pfizer is about to make a big push in cancer. Will investors listen?

knowledge

explore

knowledge

Jerome Adams on the need for new antivirals for Covid

Abridge raises $150m as clinical notes automation market heats up

Medicare proposal to cover medical devices draws a mixed reaction

New CMS data security rules will hurt Medicare, Medicaid research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

NEJM study measures Covid brain fog, impact on IQ

Medical leaders decry Supreme Court decision on affirmative action

Ukraine seeks to reclaim its role as a hub for clinical trials

After affirmative action ruling, medical educators look to 'holistic review'

Ukraine seeks to reclaim its role as a hub for clinical trials

hotspot

Neuroscience renaissance leads to new crop of psychiatric drugs

Readout Newsletter: Beam, Prozac, "TechBio" and more

Medicare Advantage isn’t working — for anyone

'Vaccine

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Reporting on presidential health from Reagan to Trump and Biden

hotspot

knowledge

explore

leisure time